The correlation between malignant tumors and kidney injury has garnered increasing attention in recent years. As a high blood flow organ, the kidney is particularly vulnerable to systemic diseases, especially malignancies. The relationship between malignant tumors and kidney damage can be explored from several angles, including the direct impact of the tumor on the kidney, treatment-induced kidney damage, and tumor-related metabolic and immune abnormalities.
The research topic aims to address critical issues surrounding kidney damage in the context of malignancies. It will explore the direct impact of tumors on kidney function, particularly focusing on malignancies like renal cell carcinoma that can cause local destruction of renal structures or lead to decreased kidney function through metastasis and systemic inflammation. Another major area of focus is the nephrotoxicity of various anticancer therapies, including chemotherapy, immunotherapy, and targeted treatments, which can lead to acute kidney injury, immune-mediated nephritis, and renal impairment. Additionally, the issue will examine how metabolic and immune disorders associated with malignancies, such as tumor lysis syndrome and paraneoplastic syndromes, can further impair kidney function. The impact of renal insufficiency on cancer treatment, including the need for adjusted dosing of chemotherapy in patients with chronic kidney disease, will also be covered. By addressing these topics, the issue seeks to advance understanding and improve strategies for managing kidney damage in cancer patients, thus enhancing overall patient outcomes.
We welcome contributions in the form of original research, reviews, mini-reviews, clinical trials, and case reports. Topics of interest include cellular and molecular mechanisms of tumorigenesis and progression, diagnostic and prognostic biomarkers, advances in therapeutic strategies, and insightful case studies providing in-depth analysis of clinical experiences and management strategies. The scope of this research topic encompasses, but not limited to, the following specific themes:
• Direct kidney damage caused by tumors, including renal cell carcinoma and the effects of tumor-related systemic inflammation.
• Nephrotoxicity of anticancer therapies such as platinum-based drugs, immune checkpoint inhibitors, and targeted therapies.
• Metabolic and immune disorders associated with malignancies, including tumor lysis syndrome and paraneoplastic syndromes affecting the kidneys.
• Impact of renal insufficiency on cancer treatment, including adjustments needed for chemotherapy dosing in patients with chronic kidney disease.
Keywords:
malignant tumors, kidney damage, nephrotoxicity, metabolic and immune disorders, cancer treatment adjustments
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
The correlation between malignant tumors and kidney injury has garnered increasing attention in recent years. As a high blood flow organ, the kidney is particularly vulnerable to systemic diseases, especially malignancies. The relationship between malignant tumors and kidney damage can be explored from several angles, including the direct impact of the tumor on the kidney, treatment-induced kidney damage, and tumor-related metabolic and immune abnormalities.
The research topic aims to address critical issues surrounding kidney damage in the context of malignancies. It will explore the direct impact of tumors on kidney function, particularly focusing on malignancies like renal cell carcinoma that can cause local destruction of renal structures or lead to decreased kidney function through metastasis and systemic inflammation. Another major area of focus is the nephrotoxicity of various anticancer therapies, including chemotherapy, immunotherapy, and targeted treatments, which can lead to acute kidney injury, immune-mediated nephritis, and renal impairment. Additionally, the issue will examine how metabolic and immune disorders associated with malignancies, such as tumor lysis syndrome and paraneoplastic syndromes, can further impair kidney function. The impact of renal insufficiency on cancer treatment, including the need for adjusted dosing of chemotherapy in patients with chronic kidney disease, will also be covered. By addressing these topics, the issue seeks to advance understanding and improve strategies for managing kidney damage in cancer patients, thus enhancing overall patient outcomes.
We welcome contributions in the form of original research, reviews, mini-reviews, clinical trials, and case reports. Topics of interest include cellular and molecular mechanisms of tumorigenesis and progression, diagnostic and prognostic biomarkers, advances in therapeutic strategies, and insightful case studies providing in-depth analysis of clinical experiences and management strategies. The scope of this research topic encompasses, but not limited to, the following specific themes:
• Direct kidney damage caused by tumors, including renal cell carcinoma and the effects of tumor-related systemic inflammation.
• Nephrotoxicity of anticancer therapies such as platinum-based drugs, immune checkpoint inhibitors, and targeted therapies.
• Metabolic and immune disorders associated with malignancies, including tumor lysis syndrome and paraneoplastic syndromes affecting the kidneys.
• Impact of renal insufficiency on cancer treatment, including adjustments needed for chemotherapy dosing in patients with chronic kidney disease.
Keywords:
malignant tumors, kidney damage, nephrotoxicity, metabolic and immune disorders, cancer treatment adjustments
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.